Comment je traite.... Le cancer avance du pancreas par une approche innovante dirigee contre les nouvelles cibles

[en] A better knowledge of fundamental mechanisms of carcinogenesis allows the development of novel therapeutic tools specifically targeting the cancer cell. Our understanding of cellular and molecular mechanisms controlling cellular cycle and cell survival is an important step for new anti-cancer treatments. This review will focus on new therapeutic's strategies in advanced pancreatic cancer.

Disciplines :

Hematology

Author, co-author :

Polus, Marc ; Centre Hospitalier Universitaire de Liège - CHU > Gastro-Entérologie-Hépatologie

Bours, Vincent ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Génétique générale et humaine

Jerusalem, Guy ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale

Sautois, Brieuc ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale

Fillet, Georges ; Université de Liège - ULiège > Département des sciences cliniques > Hématologie - Oncologie médicale

Language :

French

Title :

Comment je traite.... Le cancer avance du pancreas par une approche innovante dirigee contre les nouvelles cibles

Alternative titles :

[en] How I Treat...Advanced Cancer of the Pancreas with a Novel Approach Directed against New Targets

Publication date :

July 2002

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

428-32

Peer reviewed :

Peer reviewed

Available on ORBi :

since 31 March 2009

Statistics

Number of views

131 (4 by ULiège)

Number of downloads

73 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Polus M., Jerusalem G., Sautois B. (2002) Comment je traite...un cancer du pancréas avancé. Rev Med Liège 57:131-134.
Reni M., Passoni P., Panucci M.G. (2001) Definitive results of a phase II trial of Cisplatin, epirubicin, continuous-infusion fluorouracil, and Gemcitabine in stage IV pancreatic adenocarcinoma. JCO 19:2679-2686.
Almoguera C., Shibata D., Forrester K. (1998) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53:549-554.
Yamanaka Y., Friess H., Kobrin M.S. (1993) Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 13:565-569.
Safran H., Steinhoff M., Mangray S. (2001) Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am J Clin Oncol 24:496-499.
Simon B., Weinel R., Hohne M. (1994) Frequent alterations of the tumor suppressor genes p53 and DCC in human pancreatic carcinoma. Gastroenterology 106:1645-1651.
Moskaluk C.A., Hruban R.H., Kern S.E. (1997) p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 57:2140-2143.
Hahn S.A., Schutte M., Hoque A.T. (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271:350-353.
Jones L., Ghaneh P., Humphreys M. (1999) The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer. Ann N Y Acad Sci 880:288-307.
Gjertsen M.K., Bakka A., Breivik J. (1995) Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding ras mutation. Lancet 346:1399-1400.
Gjertsen M.K., Buanes T., Rosseland A.R. (2001) Intradermal ras peptide vaccination with granulocyte macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 92:441-450.
Adjei A.A., Davis J.N., Bruzek L.M. (2001) Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin Cancer Res 7:1438-1445.
Lersch C., Van Cutsem E., Amado R. (2001) Randomised phase II study of SCH 66336 and Gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas. Proc Asco , abstract 608; 20.
Overholser J.P., Prewett M.C., Hooper A.T. (2000) Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 89:74-82.
Bruns C.J., Harbison M.T., Davis D.W. (2000) Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 6:1936-1948.
Abbruzzese J.L., Rosenberg A., Xiong Q. (2001) Phase II study of anti-epidermal growth factor receptor (EGFR) antibody Cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer. Proc Asco , Abstract 518; 20.
Woodburn J., Kendrew J., Fennel M. (2000) ZD 1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI): Correlation of c-fos expression and tumor growth inhibition. Proc Am Ass Cancer Res , Abstract 2552; 41:402.
Meric J.B., Faivre S., Monnerat C. (2000) ZD 1839 "Iressa". Bull Cancer 87:873-876.
Baselga J., Averbuch S.D. (2000) ZD 1839 (Iressa) as an anticancer agent. Drugs 60(SUPPL. 1):33-40.
Safran H., Ramanathan R., Schwartz J. (2001) Herceptin and Gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Proc Asco , Abstract 517; 20.
Stuart R.C., Hawkins C.A., McCulloch P. (2000) A randomised double-blind placebo-controlled study of marimastat in patients with inoperable gastric carcinoma. Proc Asco , Abstract 929; 17.
Zervos E.E., Norman J.G., Gower W.R. (1997) Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo. J Surg Res 69:367-371.
Rosemurgy A., Harris J., Langleben A. (1999) Marimastat in patients with advanced pancreatic cancer: A dose-finding study. Am J Clin Oncol 22:247-252.
Evans J.D., Stark A., Johnson C.D. (2001) A phase II trial of marimastat in advanced pancreatic cancer. Br J Cancer 85:1865-1870.
Bramhall S.R., Rosemurgy A., Brown P.D. (2001) Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomised trial. JCO 19:3447-3455.
Carmichael J., Ledermann J.A., Woll P.J. (1998) Phase Ib study of concurrent administration of marimastat ang gemcitabine in non-resectable pancreatic cancer. Proc Asco , Abstract 888; 17.
Moore M.J., Hamm J., Eisenberg P. (2000) A comparison between gemcitabine and BAY 12-9566 in patients with advanced pancreatic cancer. Proc Asco , Abstract 930; 19.